BIND Biosciences, Inc. Granted Five U.S. Patents for its Medicinal Nanoengineering® Platform and Lead Drug Candidate, BIND-014

CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, announced today that the United States Patent and Trademark Office (USPTO) has recently granted five U.S. patents to the Company, bringing the total patents issued to the Company in 2012 to ten. These patents cover BIND-014, the Company’s lead Accurin product candidate in Phase 1 clinical development for the treatment of solid tumor cancers, and BIND’s Medicinal Nanoengineering® platform, which enables the design, engineering and manufacturing of Accurins with unprecedented control over drug properties to maximize trafficking to disease sites.